Home / Business and Economy / U.S. Tariffs Rattle Indian Markets as Sensex, Nifty Plunge

U.S. Tariffs Rattle Indian Markets as Sensex, Nifty Plunge

Summary

  • U.S. imposes steep tariffs on India, reaffirming 25% duty
  • Indian benchmark indices Sensex and Nifty50 open lower
  • Sun Pharma reports 20% decline in Q1 FY26 net profit
U.S. Tariffs Rattle Indian Markets as Sensex, Nifty Plunge

As of August 1, 2025, the Indian benchmark indices Sensex and Nifty50 have opened lower following the U.S. government's imposition of steep tariffs on several trading partners, including reaffirming a 25% duty on imports from India. Investors have largely viewed the tariff announcement as a pressure tactic by the U.S. and remain hopeful of a resolution through ongoing negotiations.

At around 9:20 am on August 1, 2025, the BSE Sensex was down 266 points, or 0.33%, at 80,918, while the Nifty50 declined 43 points, or 0.17%, to 24,723. This comes after both indices had fallen as much as 0.9% during the previous trading session on July 31, 2025, before trimming losses to end 0.4% lower.

In addition to India, the U.S. has also raised tariffs to 35% from 25% on imports from Canada and imposed duties of 20% and 19% on Taiwan and Thailand, respectively. Within the Sensex pack, Sun Pharma, M&M, Tata Steel, Tata Motors, Infosys, and L&T opened in the red, while HUL, ITC, Asian Paints, Kotak Mahindra Bank, Trent, and Bajaj Finance saw early gains.

Sun Pharma, in particular, dropped nearly 5% in early trade after the drugmaker reported a 20% year-on-year decline in consolidated net profit to Rs 2,278 crore for Q1FY26, down from Rs 2,836 crore in the same quarter last year.

Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.

FAQ

The U.S. tariffs on imports from India caused the Indian benchmark indices Sensex and Nifty50 to open lower on August 1, 2025, with the Sensex down 266 points and the Nifty50 declining 43 points.
Sun Pharma, a major Indian pharmaceutical company, reported a 20% year-on-year decline in its consolidated net profit to Rs 2,278 crore for Q1 FY26, down from Rs 2,836 crore in the same quarter last year.
Investors largely viewed the U.S. tariff announcement as a pressure tactic and remained hopeful for a resolution through ongoing negotiations between the U.S. and India.

Read more news on